Literature DB >> 20615966

Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2.

Berna S Sayan1, Ai Li Yang, Franco Conforti, Paola Tucci, Maria Cristina Piro, Gareth J Browne, Massimiliano Agostini, Sergio Bernardini, Richard A Knight, Tak W Mak, Gerry Melino.   

Abstract

p73 is a p53-related transcription factor with fundamental roles in development and tumor suppression. Transcription from two different promoters on the p73 gene results in generation of transcriptionally active TAp73 isoforms and dominant negative DeltaNp73 isoforms with opposing pro- and anti-apoptotic functions. Therefore, the relative ratio of each isoform is an important determinant of the cell fate. Proteasomal degradation of p73 is mediated by polyubiquitination-dependent and -independent processes both of which appear, thus far, to lack selectivity for the TAp73 and DeltaNp73 isoforms. Here, we describe the characterization of another transcriptional target of TAp73; a ring finger domain ubiquitin ligase p73 Induced RING 2 protein (PIR2). Although PIR2 was initially identified a p53-induced gene (p53RFP), low abundance of PIR2 transcript in mouse embryonic fibroblasts of TAp73 KO mice compared with WT mice and comparison of PIR2 mRNA and protein levels following TAp73 or p53 overexpression substantiate TAp73 isoforms as strong inducers of PIR2. Although PIR2 expression was induced by DNA damage, its expression did not alter apoptotic response or cell cycle profile per se. However, coexpression of PIR2 with TAp73 or DeltaNp73 resulted in an increase of the TA/DeltaNp73 ratio, due to preferential degradation of DeltaNp73. Finally, PIR2 was able to relieve the inhibitory effect of DeltaNp73 on TAp73 induced apoptosis following DNA damage. These results suggest that PIR2, by being induced by TAp73 and degrading DeltaNp73, differentially regulates TAp73/DeltaNp73 stability, and, hence, it may offer a therapeutic approach to enhance the chemosensitivity of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615966      PMCID: PMC2919933          DOI: 10.1073/pnas.0911828107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe Ki; Satoru Todo; Hiroyuki Mizuguchi; Takao Hayakawa; Akira Nakagawara
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.

Authors:  Stefania Vossio; Emanuele Palescandolo; Natalia Pediconi; Francesca Moretti; Clara Balsano; Massimo Levrero; Antonio Costanzo
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

3.  Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript.

Authors:  B M Pützer; S Tuve; A Tannapfel; T Stiewe
Journal:  Cell Death Differ       Date:  2003-05       Impact factor: 15.828

4.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

Authors:  Daniele Bergamaschi; Milena Gasco; Louise Hiller; Alexandra Sullivan; Nelofer Syed; Giuseppe Trigiante; Isik Yulug; Marco Merlano; Gianmauro Numico; Alberto Comino; Marlene Attard; Olivier Reelfs; Barry Gusterson; Alexandra K Bell; Victoria Heath; Mahvash Tavassoli; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

5.  p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1.

Authors:  Ching-Ching Ng; Hirofumi Arakawa; Seisuke Fukuda; Hisato Kondoh; Yusuke Nakamura
Journal:  Oncogene       Date:  2003-07-10       Impact factor: 9.867

6.  p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation.

Authors:  Gerry Melino; Francesca Bernassola; Marco Ranalli; Karen Yee; Wei Xing Zong; Marco Corazzari; Richard A Knight; Doug R Green; Craig Thompson; Karen H Vousden
Journal:  J Biol Chem       Date:  2003-11-21       Impact factor: 5.157

Review 7.  p73: Friend or foe in tumorigenesis.

Authors:  Gerry Melino; Vincenzo De Laurenzi; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

8.  DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur.

Authors:  C Maisse; E Munarriz; D Barcaroli; G Melino; V De Laurenzi
Journal:  Cell Death Differ       Date:  2004-06       Impact factor: 15.828

Review 9.  Functional regulation of p73 and p63: development and cancer.

Authors:  Gerry Melino; Xin Lu; Milena Gasco; Tim Crook; Richard A Knight
Journal:  Trends Biochem Sci       Date:  2003-12       Impact factor: 13.807

10.  DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.

Authors:  Alex I Zaika; Neda Slade; Susan H Erster; Christine Sansome; Troy W Joseph; Michael Pearl; Eva Chalas; Ute M Moll
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  38 in total

1.  Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress.

Authors:  Jason A Lehman; David L Waning; Christopher N Batuello; Rocky Cipriano; Madhavi P Kadakia; Lindsey D Mayo
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

2.  Analysis of the oligomeric state and transactivation potential of TAp73α.

Authors:  L M Luh; S Kehrloesser; G B Deutsch; J Gebel; D Coutandin; B Schäfer; M Agostini; G Melino; V Dötsch
Journal:  Cell Death Differ       Date:  2013-03-29       Impact factor: 15.828

3.  High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Authors:  Antonio R Lucena-Araujo; Haesook T Kim; Carolina Thomé; Rafael H Jacomo; Raul A Melo; Rosane Bittencourt; Ricardo Pasquini; Katia Pagnano; Ana Beatriz F Glória; Maria de Lourdes Chauffaille; Melina Athayde; Carlos S Chiattone; Ingrid Mito; Rodrigo Bendlin; Carmino Souza; Cristina Bortolheiro; Juan L Coelho-Silva; Stanley L Schrier; Martin S Tallman; David Grimwade; Arnold Ganser; Nancy Berliner; Raul C Ribeiro; Francesco Lo-Coco; Bob Löwenberg; Miguel A Sanz; Eduardo M Rego
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

Review 4.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

Review 5.  The p53 circuit board.

Authors:  Kelly D Sullivan; Corrie L Gallant-Behm; Ryan E Henry; Jean-Luc Fraikin; Joaquín M Espinosa
Journal:  Biochim Biophys Acta       Date:  2012-02-07

6.  p73 in Cancer.

Authors:  Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight
Journal:  Genes Cancer       Date:  2011-04

7.  Regulation of RNF144A E3 Ubiquitin Ligase Activity by Self-association through Its Transmembrane Domain.

Authors:  Shiuh-Rong Ho; Yu-Ju Lee; Weei-Chin Lin
Journal:  J Biol Chem       Date:  2015-07-27       Impact factor: 5.157

8.  TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function.

Authors:  Jin Zhang; Enshun Xu; Xinbin Chen
Journal:  J Biol Chem       Date:  2013-01-29       Impact factor: 5.157

9.  RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage.

Authors:  Shiuh-Rong Ho; Christina S Mahanic; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

10.  Disruption of chromosomal locus 1p36 differentially modulates TAp73 and ΔNp73 expression in follicular lymphoma.

Authors:  Hesham M Hassan; Michelle L Varney; Smrati Jain; Dennis D Weisenburger; Rakesh K Singh; Bhavana J Dave
Journal:  Leuk Lymphoma       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.